Un­der-the-radar Chi­nese biotech scores $47M up­front in se­cre­tive Mer­ck deal around can­cer drug

Dur­ing his most re­cent in­vestor call, Mer­ck CEO Rob Davis promised to be “ap­pro­pri­ate­ly ag­gres­sive in pur­su­ing com­pelling ex­ter­nal in­no­va­tion.” But as it turns out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER